MedTrace Logo

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

NCT03556956 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2020-12-08

No results posted yet for this study

Summary

A prospective, multicentre, open-label, randomized, phase 2-3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

Masitinib

Tyrosine kinase inhibitor

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Julien Taieb, MD · Hôpital Européen Georges Pompidou, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • Czechia
  • France
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03556956 on ClinicalTrials.gov